Get in touch with Matt

Submit

Thank you

About Matt

Matt graduated from UCL in 2017 with a bachelor’s degree in Biochemistry. He subsequently obtained a master’s degree entitled ‘Cellular Therapy from Bench to Market’, a program which blended biology and business to explore the science, regulation and routes to market underpinning advanced therapies. His thesis was a business plan to commercialise a stem cell-derived therapy for Parkinson’s disease. Following this, Matt joined the Cell and Gene Therapy Catapult as a laboratory technician gaining experience in ddPCR, cell culture, non-viral gene editing techniques, flow cytometry, as well as upstream and downstream processing of AAV (viral vector) for gene therapy applications.

Matt joined Keltie in 2022 following three years training at another leading patent law firm. He is part-qualified and working towards European and UK qualification.

 

Matt particularly enjoys working closely with clients to understand not only the detail behind their technology, but the business needs behind their intellectual property. He has experience in both drafting and prosecution, advising multinational pharmaceutical clients and early-stage spin-outs in a range of fields including antibodies, cell and gene therapies, small molecules and nanotechnologies.

More
Patents, plausibility and data: one year on from G 2/21

02.04.2024

Patents, plausibility and data: one year on from G 2/21

On 23 March 2023, the European Patent Office (EPO) Enlarged Board of Appeal (EBA) published its decision in case G 2/21, concerning plausibility in patent applications. The decision provided useful guidance on how much data needs to be disclosed in a patent application to overcome objections based on the grounds of lack of inventive step and insufficiency. One year on, we take a look at how the EPO has been applying this standard in the life sciences field.

More
UPC Court of Appeal reverses Preliminary Injunction in first substantive decision

21.03.2024

UPC Court of Appeal reverses Preliminary Injunction in first substantive decision

The Court of Appeal of the Unified Patent Court (UPC) recently published its first decision considering substantive issues, in which it overturned a first instance decision of the Munich local division (NanoString (appellants) v 10x Genomics (respondents), UPC_CoA_335/2023).

Get in touch with Matt

Submit

Thank you